Associated Press/Oct. 9, 2012
Federal Trade Commission (FTC) Chairman Jon Leibowitz speaking at the Justice Department in Washington.
About this Article
The Supreme Court will take a close look at payments from brand-name drug makers to manufacturers of generic equivalents to keep the no-name products off the market at an estimated cost of $3.5 billion a year to consumers.